DGAP-News: Apricus Biosciences to Present at BIO-Europe Spring 2013

| Source: EQS Group AG
Apricus Biosciences, Inc. 

07.03.2013 14:00

SAN DIEGO, 2013-03-07 14:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com) announced today that Edward Cox, Vice President Corporate
Development & Investor Relations, will present at the BIO-Europe Spring 2013
Partnering Conference, being held in Barcelona, Spain. Mr. Cox's presentation
will take place on Wednesday, March 13, 2013 at 11:00 a.m. Local Time (6:00
a.m. Eastern Time). 

A replay of the presentation will be accessible to the public online at the
Company's website at http://www.apricusbio.com. 

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
large-market therapeutic classes including male and female sexual health. The
Company has one approved product, Vitaros(r), for the treatment of erectile
dysfunction, which will be marketed in Canada by Abbott Laboratories and
Femprox(r), a product candidate, for the treatment of female sexual arousal
disorder, which successfully completed one 400-patient Phase III study in

For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio. 

         CONTACT: Apricus Bio Investor Relations:
         David Pitts
         Argot Partners
News Source: NASDAQ OMX

07.03.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      Apricus Biosciences, Inc.
              United States
ISIN:         US9901429525
End of Announcement                             DGAP News-Service